| Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| Is blood transfusion safe during the COVID-19 pandemic? |
|
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Novel therapeutic choices in immune aplastic anemia |
|
F1000Research |
Aplastic Anemia |
| Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. |
|
PloS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Pitfalls in Assessing Response to Treatment in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| New Approaches for Anemia in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| The Problem of TP53-Mutant MDS/AML |
|
Clinical Lymphoma , Myeloma & Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
